Mylan NV (MYL)

17.27
0.04 0.23
NASDAQ : Health Technology
Prev Close 17.23
Open 17.33
Day Low/High 17.16 / 17.43
52 Wk Low/High 16.63 / 35.16
Volume 5.29M
Avg Volume 5.83M
Exchange NASDAQ
Shares Outstanding 516.13M
Market Cap 9.14B
EPS 0.70
P/E Ratio 196.67
Div & Yield N.A. (N.A)
Trending Tickers: MYL, MNK, VRX, CHK, UA

Trending Tickers: MYL, MNK, VRX, CHK, UA

Rising oil prices helped buoy U.S. markets Friday.

Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians

Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians

Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.

S&P 500 Poised to Shake Off Summer Doldrums

S&P 500 Poised to Shake Off Summer Doldrums

Jobs and GDP reports plus a possible rate hike are setting up the market for big moves.

2 Biotechs to Watch Ahead of the Election

2 Biotechs to Watch Ahead of the Election

These 2 small-caps have strong pipelines and are becoming analyst darlings.

Big Pharma Has No Rx for Viral Social Media Reactions

Big Pharma Has No Rx for Viral Social Media Reactions

Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.

5 Winning Stocks That Could Be Ready to Drop

5 Winning Stocks That Could Be Ready to Drop

Past price action does not guarantee future price action.

Mylan Lowers Prices on EpiPens But Jim Cramer Still Doesn't Like the Stock

Mylan Lowers Prices on EpiPens But Jim Cramer Still Doesn't Like the Stock

Mylan seeks to quell public outrage of its EpiPen Pricing with a generic version of the product.

Mylan Shares Jump on Discounted EpiPen Offering

Mylan Shares Jump on Discounted EpiPen Offering

The drugmaker's shares are higher after announcing the discounted allergy treatment.

U.S. Stocks Rise as Investors Weigh September Rate Hike; Mylan to Offer Generic EpiPen

U.S. Stocks Rise as Investors Weigh September Rate Hike; Mylan to Offer Generic EpiPen

U.S. stocks are higher Monday, as investors continued to digest comments on interest rates from Federal Reserve Chair Janet Yellen on Friday.

Morning Movers: HLF, MYL, WLL, HOG

Morning Movers: HLF, MYL, WLL, HOG

Herbalife shares were climbing after Carl Icahn heated up his long-running spat with Bill Ackman.

Cramer: The Answer to This Market: Part 1

Cramer: The Answer to This Market: Part 1

The leadership is quite stark.

Trader's Daily Notebook: Is It Worth Trying to Catch a Bottom in Biotechs?

Trader's Daily Notebook: Is It Worth Trying to Catch a Bottom in Biotechs?

The recent harsh spotlight on the sector raises the question.

As Predictable As the Sun Rising

Some things are just so predictable: The business media will inundate us with hours of "analysis" of Mylan this week. Yet, though time-consumptive, the dialogue on Mylan will not likely be particularly revealing. (Thirty minutes would have sufficed)...

Jim Cramer Explains How Mylan is Able to Get Away With High Prices on EpiPens Even in the Face of Criticism

Jim Cramer Explains How Mylan is Able to Get Away With High Prices on EpiPens Even in the Face of Criticism

More competition in the drug industry would prevent situations like the big price hike in Mylan's EpiPens, according to Jim Cramer.

Cramer: Getting to the Heart -- or the Lack of It -- of the EpiPen Issue

Cramer: Getting to the Heart -- or the Lack of It -- of the EpiPen Issue

Competition could be the cure, not demonizing the drugmaker's CEO.

Mylan to Offer Savings Card on EpiPen After Controversial 400% Price Increase

Mylan to Offer Savings Card on EpiPen After Controversial 400% Price Increase

After Mylan raised the price of its EpiPen by 400 percent, sparking a wave of controversy, the company now saying it will offer a savings card worth $300 to users.

U.S. Stocks Slip on Yellen Worries; Dollar General Shares Slip on Earnings

U.S. Stocks Slip on Yellen Worries; Dollar General Shares Slip on Earnings

U.S. stocks moved slightly lower on Thursday as investors anxiously await remarks from Federal Reserve Chair Janet Yellen on Friday.

Mylan EpiPen Controversy Puts More Biotechs in Danger

Mylan EpiPen Controversy Puts More Biotechs in Danger

You can bet that at the next hint of an unfair price hike, politicians will be waiting to pounce.

Mylan Dispute Puts More Biotechs in Danger

Mylan Dispute Puts More Biotechs in Danger

You can bet that at the next hint of an unfair price hike, politicians will be waiting to pounce.

Mallinckrodt's Top Drug Could Go the Way of EpiPen

Mallinckrodt's Top Drug Could Go the Way of EpiPen

The drug that's helping boost the company's stock could become its biggest risk.

Morning Movers: SHLD, TIF, DG, DLTR, MYL

Morning Movers: SHLD, TIF, DG, DLTR, MYL

The discount dollar stores quarterly results disappoint, while Tiffany beats profit forecasts.

Rev's Forum: Market Resets, Waiting for Janet Yellen

Rev's Forum: Market Resets, Waiting for Janet Yellen

The indexes' positive tone shifted in the last two days.

Cramer: The Stock Market Is Helping the Consumer This Year

Cramer: The Stock Market Is Helping the Consumer This Year

It could well be the stock market, not the Fed, that is driving our retail and services.

Cramer: It's a Presidential Campaign, So Let the Corporate Bashing Begin

Cramer: It's a Presidential Campaign, So Let the Corporate Bashing Begin

Clinton goes after the drug companies again -- for starters.

Ugly Underlying Action Should Stay Hidden

Ugly Underlying Action Should Stay Hidden

Market momentum cools, big time.

Closing Bell: Clinton Calls Out Mylan on Price Hikes; U.S. Stock Losses Grow

Closing Bell: Clinton Calls Out Mylan on Price Hikes; U.S. Stock Losses Grow

U.S. stock losses grew heavier Wednesday as the afternoon wore-on with a selloff in crude oil and health care stocks leading Wall Street into the red.

Jim Cramer: Perrigo is Problematic

Jim Cramer: Perrigo is Problematic

Perrigo might have been in more of a decline than the market realized when it turned down Mylan's $26 billion offer for the company last year, says Jim Cramer.

Tennis Legend Billie Jean King Wants to Make the Sport More Like Basketball

Tennis Legend Billie Jean King Wants to Make the Sport More Like Basketball

Tennis icon Billie Jean King co-founded World Team Tennis (WTT) in 1974 and the organization's intent resonates more today than ever before with tennis fans.

Mylan's Weakness Shouldn't Last, So Buy Now

Mylan's Weakness Shouldn't Last, So Buy Now

An investor should make good money on any turn in the drug maker's business or in investor sentiment.

Where Is the Insider Buying?

The market is off its worst levels of the day. Big biotech and biopharma are providing strength today, with Biogen , Gilead Sciences and Mylan all sporting solid gains in a down market. Energy has made a bit of a comeback, but still is down nearly 2...